NCT04798716 - The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2024

Conditions

Covid19Novel Coronavirus PneumoniaAcute Respiratory Distress Syndrome

Interventions

DRUG

MSC-exosomes delivered intravenously every other day on an escalating dose: (2:4:8)

Escalating dose 2 X 10\^9, 4 X 10\^9, 8 X 10\^9/mL

DRUG

MSC-exosomes delivered intravenously every other day on an escalating dose (8:4:8)

Escalating dose 8 X 10\^9, 4 X 10\^9, 8 X 10\^9 mL

DRUG

MSC-exosomes delivered intravenously every other day (8:8:8)

Dosed 8 X 10\^9, 8 X 10\^9, 8 X 10\^9 mL

Trial Locations (1)

Mission Community Hospital, Panorama City